Is Gliclazide Associated with a Lower Obesity-Related Cancer Risk Compared to Other Sulfonylureas? A Long-term Prospective Cohort Study.

Jing de Haan-DuNanno KleefstraDennis SchrijndersKlaas H GroenierGeertruida H de BockGijs W D Landman

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2020)

Gliclazide is not preferred over other sulfonylureas regarding obesity-related cancer risk.

Keyphrases

insulin resistance
metabolic syndrome
weight loss
type diabetes
high fat diet induced
weight gain
adipose tissue
physical activity
skeletal muscle
drug induced